−1820KRW
−23.04 BKRW
78.03 BKRW
7.67 M
About HANS BIOMED
Sector
Industry
CEO
Geun-Young Kim
Website
Headquarters
Seoul
Employees (FY)
244
Founded
1999
ISIN
KR7042520007
FIGI
BBG000D25585
Hans Biomed Corp. engages in the manufacture and sale of graft material and silicon products. Its products include skin and bone graft material, silicon material, and other medical appliances. The company was founded on September 15, 1999 and is headquartered in Seoul, South Korea.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 042520 is 13230 KRW — it has increased by 0.08% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange HANS BIOMED stocks are traded under the ticker 042520.
042520 stock is 3.44% volatile and has beta coefficient of 0.93. Check out the list of the most volatile stocks — is HANS BIOMED there?
HANS BIOMED revenue for the last quarter amounts to 16.70 B KRW despite the estimated figure of 19.10 B KRW. In the next quarter revenue is expected to reach 20.30 B KRW.
Yes, you can track HANS BIOMED financials in yearly and quarterly reports right on TradingView.
042520 stock has fallen by 3.15% compared to the previous week, the month change is a 11.27% fall, over the last year HANS BIOMED has showed a 9.20% decrease.
042520 net income for the last quarter is −1.02 B KRW, while the quarter before that showed −8.51 B KRW of net income which accounts for 87.98% change. Track more HANS BIOMED financial stats to get the full picture.
Today HANS BIOMED has the market capitalization of 171.69 B, it has decreased by 2.48% over the last week.
Like other stocks, 042520 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANS BIOMED stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 244.00 employees. See our rating of the largest employees — is HANS BIOMED on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANS BIOMED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANS BIOMED stock shows the strong sell signal. See more of HANS BIOMED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HANS BIOMED EBITDA is 1.73 B KRW, and current EBITDA margin is 0.53%. See more stats in HANS BIOMED financial statements.